Yazar "Ayhan, Huseyin" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    Association between electrocardiographic parameters and collateral circulation in patients with chronic total occlusion
    (2020) Duran Karaduman, Bilge; Ayhan, Huseyin; Bozkurt, Engin; Keles, Telat
    Aim: In patients with chronic total occlusion (CTO), negative cardiovascular outcomes (angina, more frequent ventricular arrhythmias, higher mortality) and reduced survival have been demonstrated. The association between several electrocardiogram (ECG) markers, revealing individuals at high risk for ventricular arrhythmia, and collateral has been investigated in different studies in coronary artery disease patients. In this study, we aimed to investigate the association between the electrocardiographic parameters between good coronary collateral group and poor coronary collateral group in CTO patients with PCI.Material and Methods: Patients retrospectively implemented CTO PCI to those with symptomatic symptoms of myocardial ischemia or with the exact sign of ischemia in the CTO area. The patients were divided into 2 groups according to the Rentrop class: group 1 (Rentrop 0 and 1) and group 2 (Rentrop 2 and 3). Baseline characteristics, laboratory and ECGs, procedural data, and outcome data were retrospectively collected. Results: In this study included 59 CTO patients undergoing PCI. Mean age was 61.0±10.3 years and 43 (72.9%) of patients were male, and PCI success was 69.4%. While 22 (37.2%) of the patients were poor collateral group 1 (Rentrop 0 and 1), the remaining 37 (62.3%) of them were good collateral group 2 (Rentrop 2 and 3). There was a significant difference, in poor and good collateral groups, QT dispersion (77.2±27.9 vs 66.5±22.5, p: 0.041, respectively), QTc dispersion (82.1±26.9 vs 70.4±23.9, p: 0.034, respectively), and the presence of fQRS (63.6% vs 43.2, p: 0.027, respectively). But there was no statistically difference in P wave dispersion (48.0±9.5 vs 47.2±11.3, p: 0.796). Correlation analysis reported the association between Rentrop classification and Syntax score (r: -0.397, p: 0.002), LDL-C (r: -0.198, p: 0.025), QT dispersion (r: -0.156, p: 0.045), QTc dispersion (r: -0.176, p: 0.037), and the presence of fQRS (r: 0.234, p: 0.021) were statistically significant.Conclusion: We suggest that some ECG parameters are an important, easy, simple, and cost effective tool and can be beneficial in predicting the poor or good collateral in patients with CTO.
  • Küçük Resim
    Öğe
    An update of dual antiplatelet therapy
    (2017) Ayhan, Huseyin; Duran Karaduman, Bilge; Durmaz, Tahir; Keles, Telat; Bozkurt, Engin
    Since platelet activation and aggregation play a major role in thrombus formation in lumen of coronary arteries, they constitute a main target in treatment of stable ischemic heart disease and acute coronary syndromes. Antiplatelet therapy should be commenced as early as possible within the current indications in order to reduce the risk of both acute ischemic complications and recurrent atherothrombotic events. Platelet functions can be inhibited by three classes of drugs having different mechanisms of action, namely acetylsalicylic acid, P2Y12 inhibitors, and glycoprotein IIb/IIIa antagonists. Dual antiplatelet therapy (acetylsalicylic acid and P2Y12 inhibitors) have recently been a hot topic of research with the advent of stents in recent years. Multiple regimens of antiplatelet and anticoagulation therapy have been used in the past in patients undergoing percutaneous coronary intervention. The optimal duration of dual antiplatelet therapy after drug-eluting stent implantation is unclear. Many clinicians have pushed for prolonged dual antiplatelet therapy — beyond 12 months — on the assumption that extended therapy reduces recurrent cardiovascular events. Despite the established guidelines, there is not a clear consensus about how to manage antiplatelet therapy. New antiplatelet agents have been developed for patients at high risk of thrombosis. Their benefits in terms of mortality and major cardiovascular events have been demonstrated, but some concerns remain regarding the possible increase in bleeding.The aim of this review was to summarize the current literature containing the potential solutions to problems related to indications and duration of dual antiplatelet therapy and its interaction with other medications.